$50 Million for Software as Medicine
Click Therapeutics has raised $50 million in a Series D round to advance its pipeline of prescription digital therapeutics (PDTs). Unlike wellness apps, Click's products are FDA-authorized prescription treatments — software that doctors prescribe like medication.
The Pipeline
Click is developing software-based treatments for:
- Major Depressive Disorder — their lead program, in partnership with Otsuka Pharmaceutical
- Chronic Insomnia — digital CBT-I with adaptive algorithms
- Substance Use Disorders — cognitive behavioral interventions delivered via smartphone
How Prescription Digital Therapeutics Work
PDTs are software programs that deliver evidence-based therapeutic interventions directly to patients:
- Clinicians prescribe them through standard e-prescribing systems
- Patients download the app and follow structured treatment modules
- The software adapts to patient responses using machine learning
- Outcomes are shared with prescribing clinicians
Why This Matters for the Nervous System Space
Prescription digital therapeutics represent a new modality for treating nervous system conditions. Instead of modulating neurotransmitters (drugs) or electrical activity (neuromodulation), PDTs work through structured behavioral change — rewiring neural pathways through evidence-based cognitive and behavioral techniques.
The Business Model
Click's payer-aligned approach is key to its funding success:
- FDA authorization provides clinical credibility
- Prescription-only distribution creates a defensible moat
- Insurance reimbursement makes the product accessible to patients
- Real-world evidence generation attracts pharmaceutical partnerships
